This brand name is authorized in Canada, United States
The drug IBSRELA contains one active pharmaceutical ingredient (API):
|
1
Tenapanor
UNII 50605O2ZNS - TENAPANOR HYDROCHLORIDE
|
|
Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. By inhibiting NHE3, tenapanor reduces absorption of sodium from the small intestine and colon, resulting in an increase in water secretion into the intestinal lumen, which accelerates intestinal transit time and results in a softer stool consistency. It is used for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| IBSRELA Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A06AX08 | A Alimentary tract and metabolism → A06 Laxatives → A06A Laxatives → A06AX Other laxatives | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: CA | Health Products and Food Branch | Identifier(s): 02498049 |
| Country: US | FDA, National Drug Code | Identifier(s): 73154-050 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
